Vaxcyte Inc.
Cash Flow Statement
| Line Item | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-128.7M | $-95.0M | $-180.8M | $-92.7M | $-68.3M | $-60.5M | $-78.1M | $-57.9M |
| Depreciation & Amortization | $1.4M | $999.0K | $844.0K | $800.0K | $800.0K | $712.0K | $952.0K | $700.0K |
| Depreciation | — | — | — | — | — | — | — | — |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $21.6M | $17.6M | $13.3M | $13.2M | $12.5M | $9.6M | $7.0M | $6.6M |
| Net Cash from Operating Activities | $-121.4M | $-159.1M | $-128.8M | $-57.5M | $-62.7M | $-47.7M | $-65.2M | $-38.5M |
| Investing Activities | ||||||||
| Capital Expenditures | $7.8M | $5.7M | $5.3M | $7.3M | $-2.1M | $5.6M | $1.1M | $843.0K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-80.4M | $-451.1M | $-13.9M | $22.3M | $-333.6M | $-448.1M | $-36.0M | $34.7M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $110.4M | $818.2M | $2.7M | $48.6M | $547.0M | $41.6M | $656.6M | $44.0M |
| Net Change in Cash | $-92.8M | $214.1M | $-147.7M | $14.3M | $150.6M | $-454.2M | $556.3M | $40.2M |
| Free Cash Flow | $-129.2M | $-164.8M | $-134.1M | $-64.9M | $-60.6M | $-53.3M | $-66.4M | $-39.4M |